glucose, (beta-d)-isomer has been researched along with ipragliflozin in 163 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 127 (77.91) | 24.3611 |
| 2020's | 36 (22.09) | 2.80 |
| Authors | Studies |
|---|---|
| Akinlade, B; Klasen, S; Kowalski, D; Schwartz, SL; Wilpshaar, W; Zhang, W | 1 |
| Kadokura, T; Krauwinkel, WJ; Smulders, RA; Veltkamp, SA | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Noda, A; Qun, L; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 2 |
| Ikegai, K; Imamura, M; Kobayashi, Y; Koide, T; Kosakai, K; Kurosaki, E; Murakami, T; Nakanishi, K; Noda, A; Ogiyama, T; Ohkura, Y; Ohta, M; Shiraki, R; Suzuki, T; Takeuchi, M; Tomiyama, H; Yokota, M | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, WJ; Smulders, RA; van Dijk, J; Veltkamp, SA; Zhang, W | 1 |
| Collins, C; Kadokura, T; Smulders, RA; van Bruijnsvoort, M; van Dijk, J; Veltkamp, SA | 1 |
| Dhanjal, P; Ferrannini, E; Fonseca, VA; Houzer, A; Wilding, JP; Wilpshaar, W | 1 |
| Chen, LH; Leung, PS | 1 |
| Ferrannini, E; Kadokura, T; Smulders, RA; Veltkamp, SA | 1 |
| Kurosaki, E; Ogasawara, H | 1 |
| Hayashizaki, Y; Imamura, M; Kihara, R; Kobayashi, Y; Kurosaki, E; Li, Q; Noda, A; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Yamajuku, D; Yokono, M | 2 |
| Bloomgarden, Z | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, WJ; Lasseter, KC; Plumb, L; Smulders, R; Townsend, RW; Ushigome, F; Zhang, W | 1 |
| Abeyratne, A; Dietz, A; Kadokura, T; Keirns, J; Krauwinkel, W; Smulders, R; Zhang, W | 1 |
| Mauricio, D | 1 |
| Hayashizaki, Y; Kihara, R; Kurosaki, E; Li, Q; Mitsuoka, K; Miyoshi, S; Muramatsu, Y; Sasamata, M; Shibasaki, M; Tahara, A; Takasu, T; Tomiyama, H; Uchiyama, Y; Yokono, M | 1 |
| Dungo, RT; Poole, RM | 1 |
| Goto, K; Kashiwagi, A; Kazuta, K; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Chung, SH; Kim, GW | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Akiyama, N; Kadokura, T; Kageyama, S; Kashiwagi, A; Kazuta, K; Nagase, I; Smulders, R; Utsuno, A; Yoshida, S | 1 |
| Hayashizaki, Y; Kurosaki, E; Tahara, A; Takakura, S; Takasu, T | 1 |
| Kadokura, T; Keirns, J; Krauwinkel, W; Leeflang, S; Nakajo, I; Smulders, R; Taniuchi, Y; Zhang, W | 1 |
| Katakami, N; Matsuoka, TA; Shimomura, I; Shiraiwa, T; Takahara, M | 1 |
| Ishikawa, H; Kashiwagi, A; Kazuta, K; Takahashi, H; Ueyama, E; Utsuno, A; Yoshida, S | 1 |
| Kihara, Y; Nakano, Y; Sairaku, A | 1 |
| Scheen, AJ | 2 |
| Okada, J; Okada, S; Saito, T; Satoh, T; Shibusawa, R; Shimoda, Y; Tagaya, Y; Yamada, E; Yamada, M | 1 |
| Davis, SN; Hedrington, MS | 1 |
| Hayashizaki-Someya, Y; Koide, K; Kurosaki, E; Mitori, H; Takakura, S; Takasu, T; Yamazaki, S | 1 |
| Kaku, S; Takakura, S; Takasu, T | 1 |
| Ito, Y; Kobuchi, S; Sakaeda, T; Yano, K | 1 |
| Dohi, K; Fujii, E; Fujimoto, N; Ito, M; Moriwaki, K; Nakamori, S; Omori, T; Sato, Y; Takeuchi, T; Yamada, N | 1 |
| Imamura, M; Kurosaki, E; Tahara, A; Takasu, T; Yokono, M | 3 |
| Hayashi, A; Kawai, S; Shichiri, M; Takano, K | 1 |
| Fujita, K; Honda, Y; Imajo, K; Kato, S; Kato, T; Kessoku, T; Mawatari, H; Nakajima, A; Ogawa, Y; Saito, S; Tomeno, W; Yoneda, M | 1 |
| Nakamura, I; Sugamori, H; Terauchi, Y; Yokote, K | 2 |
| Hayashizaki, Y; Takakura, S; Takasu, T; Toyoshi, T | 1 |
| Isogawa, A; Ohki, T; Tagawa, K; Toda, N | 1 |
| Furuke, S; Kanno, K; Komiya, C; Miyachi, Y; Ogawa, Y; Shiba, K; Shimazu, N; Tsuchiya, K; Yamaguchi, S | 1 |
| Aihara, Y; Asada, K; Douhara, A; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Okura, Y; Takeda, K; Yoshiji, H | 1 |
| Atsumi, T; Ichiyama, M; Kameda, R; Miyoshi, H; Nakamura, A; Nomoto, H; Ono, K; Sugawara, H; Yamamoto, C; Yamamoto, K | 1 |
| Hirate, M; Kutoh, E; Murayama, T; Wada, A | 2 |
| Kashiwagi, A; Kawamuki, K; Kazuta, K; Kosakai, Y; Nakamura, I; Satomi, H; Takahashi, H; Ueyama, E; Yoshida, S | 1 |
| Hoshi, H; Niijima, Y; Okada, S; Ono, K; Osaki, A; Saito, T; Yamada, E; Yamada, M | 1 |
| Bando, H; Horasawa, S; Kawasumi, K; Ohashi, K; Osame, K; Saito, S | 1 |
| Nakamura, M; Nishio, D; Saito-Sasaki, N; Sawada, Y | 1 |
| Abiko, A; Atageldiyeva, K; Fujita, Y; Haneda, M; Honjo, J; Makino, Y; Mizumoto, K; Takeda, Y; Takiyama, Y; Yanagimachi, T | 1 |
| Cha, BS; Chuang, LM; Kokubo, S; Lu, CH; Min, KW; Yoshida, S | 1 |
| Harada, M; Kawamura, T; Miyazaki, Y; Nakayama, I; Ogura, M; Okonogi, H; Sato, H; Tokoro, K; Tsuboi, N; Yokoo, T | 1 |
| Asahina, S; Ishihara, H; Nakao, I; Okitsu, A; Yamaguchi, S | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K | 1 |
| Dicembrini, I; Mannucci, E; Monami, M | 1 |
| Ebihara, K; Ishibashi, S; Kotani, K; Okada, K; Yamazaki, H | 1 |
| Eguchi, K; Higashi, Y; Inoue, T; Ishizu, T; Kadokami, T; Kario, K; Kitakaze, M; Kodera, S; Maemura, K; Matsuhisa, M; Murohara, T; Nanasato, M; Nishio, Y; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Shimabukuro, M; Suzuki, M; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H | 1 |
| Del Gobbo, LC; Li, Y; Song, Y; Tang, H; Zhai, S; Zhang, J; Zhang, X | 1 |
| Emoto, N; Hattori, N; Nagamine, T; Nakamura, Y; Okajima, F; Sugihara, H | 1 |
| Hamada, K; Takakura, S; Takasu, T | 1 |
| Kato, H; Nagai, Y; Ohta, A; Sada, Y; Tanaka, Y | 1 |
| Atsumi, T; Miyoshi, H; Nakamura, A; Takase, T; Yamamoto, C | 1 |
| Kutoh, E; Murayama, T; Takizawa, Y; Wada, A | 1 |
| Imai, J; Katagiri, H; Kawana, Y; Sawada, S; Yamada, T | 1 |
| Kajiya, S; Kawasoe, M; Kawasoe, S; Kubozono, T; Maruguchi, Y; Miyata, M; Ohishi, M; Uenomachi, H | 1 |
| Amino, N; Hayashizaki, Y; Hirosumi, J; Kurosaki, E; Minoura, H; Takakura, S; Takasu, T | 1 |
| Hashimoto, N; Horikoshi, T; Ishikawa, K; Ishikawa, T; Kobayashi, K; Koshizaka, M; Kuribayashi, N; Nagashima, K; Sato, Y; Shimofusa, R; Takahashi, S; Takemoto, M; Tatsuno, I; Terano, T; Uchida, D; Yokote, K | 1 |
| Gao, HK; Kengne, AP; Mazidi, M; Rezaie, P | 1 |
| Ishida, H; Nakamoto, S; Osonoi, T; Osonoi, Y; Saito, M; Tamasawa, A | 1 |
| Fukagawa, M; Miyauchi, M; Toyoda, M | 1 |
| Hosoyamada, M; Ishizawa, K; Kuribayashi-Okuma, E; Shibata, S; Toyoki, D; Uchida, S; Xu, N | 1 |
| Akiyama, Y; Inoue, K; Inukai, K; Ito, D; Morimoto, Y; Noda, M; Saito, D; Shimada, A; Shimizu, S; Yanagisawa, M | 1 |
| Ishii, S; Kato, H; Nagai, Y; Nakagawa, T; Nakamura, Y; Ohta, A; Sasaki, Y; Tanaka, Y | 1 |
| Takeishi, S; Takekoshi, S; Tsuboi, H | 1 |
| Fujimori, T; Ichikawa, K; Irahara, A; Kimata, K; Koketsu, Y; Nakano, A; Senda, E; Sumida, Y; Takata, E; Takeda, A; Yamada, H | 1 |
| Iuchi, H; Kayama, Y; Matsutani, D; Minamisawa, S; Sakamoto, M; Suzuki, H; Takeda, N; Utsunomiya, K | 1 |
| Fushimi, Y; Hirukawa, H; Kaku, K; Kamei, S; Kaneto, H; Kimura, T; Kinoshita, T; Kohara, K; Mune, T; Nakanishi, S; Nishioka, M; Obata, A; Okauchi, S; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
| Maegawa, H; Nakamura, I; Tabuchi, H; Tobe, K; Uno, S | 4 |
| Kanasaki, K; Kitada, M; Koya, D; Li, J; Nitta, K; Takagaki, Y; Takagi, S; Takasu, T | 1 |
| Tahara, A; Takasu, T | 4 |
| Chang, WX; Kumagai, T; Shibata, S; Tamura, Y; Uchida, S | 1 |
| Dobashi, S; Fujii, T; Hashimoto, H; Hisatake, S; Ikeda, T; Kabuki, T; Kiuchi, S; Oka, T | 1 |
| Fukuda, T; Fukui, M; Fushimura, Y; Ikeda, K; Kamezaki, M; Kirita, Y; Kitani, T; Komaki, K; Kusaba, T; Matoba, S; Sakai, R; Shiotsu, Y; Tamagaki, K; Uehara, M; Watanabe, N; Yamashita, N; Yamazaki, M | 1 |
| Takakura, S; Takasu, T | 3 |
| Fukuda, K; Imai, T; Koepsell, H; Masuda, T; Muto, S; Nagata, D; Ohara, K; Onishi, A; Vallon, V; Watanabe, M; Watanabe, Y | 1 |
| Fujimura, Y; Fukuda, T; Horikawa, T; Motonaga, R; Nomiyama, T; Ohsako, T; Shimono, D; Tanabe, M; Terawaki, Y; Yanase, T | 1 |
| Akiyama, N; Kashiwagi, A; Kazuta, K; Kosakai, Y; Nakamura, I; Sakatani, T; Takahashi, H; Ueyama, E | 1 |
| Baik, S; Cha, BS; Chon, S; Chung, CH; Han, KA; Jung, CH; Kim, DS; Lee, IK; Lee, KW; Lee, MK; Lim, S; Park, KS; Park, S; Sakatani, T; Yoon, KH | 1 |
| Azuma, K; Iizuka, T; Inoue, K; Maruyama, S; Matsuzawa, Y; Mukai, S; Nakai, K; Nishikawa, T; Omura, M; Saito, J; Tsurutani, Y | 1 |
| Abdelazeim, B; Abdelazeim, N; El Ashal, G; Elgebaly, A; Mattar, O; Namous, L; Nasreldin, N | 1 |
| Fukuzawa, K; Haruna, M; Hayakawa, T; Hayase, T; Ito, Y; Kobuchi, S; Nakayama, H; Sakaeda, T; Sugano, A; Takahata, N; Takaoka, Y; Tohkin, M; Yoshioka, R | 1 |
| Kondo, Y; Tahara, A; Takasu, T; Tomiyama, H | 1 |
| Higashijima, Y; Inagi, R; Nangaku, M; Saito, H; Suematsu, M; Sugahara, M; Sugiura, Y; Tanaka, S; Tanaka, T; Yamaguchi, J | 1 |
| Aoki, S; Atsumi, T; Cho, KY; Ito, YM; Kurihara, Y; Manda, N; Miya, A; Miyoshi, A; Miyoshi, H; Nakamura, A; Niwa, H; Nomoto, H; Takahashi, K; Yamamoto, C | 1 |
| Komiya, C; Miyachi, Y; Mori, K; Ogasawara, N; Ogawa, Y; Shiba, K; Tsuchiya, K | 1 |
| Orlova, VL; Shestakova, MV; Tretter, R; Verbovoy, AF; Wilding, JPH; Wilpshaar, W | 1 |
| Arima, H; Fuse, K; Ida, S; Inoue, H; Kondo, K; Maegawa, H; Miura, K; Miyazawa, I; Morino, K; Murata, K; Ohashi, N; Sato, D; Sekine, O; Tanaka-Mizuno, S; Ugi, S; Yoshimura, M | 1 |
| Hara, K; Hirota, Y; Kishi, M; Komada, H; Kuroki, Y; Matsuda, T; Miura, H; Ogawa, W; Ohara, T; Okada, Y; Otowa-Suematsu, N; Sakaguchi, K; So, A; Takeda, A; Tamori, Y; Yamada, T; Yokota, K | 1 |
| Fujii, S; Fujiwara, H; Gunji, R; Kakiuchi, S; Kaku, K; Kameda, H; Kurihara, Y; Senda, M; Tamura, M; Utsunomiya, K | 1 |
| Maegawa, H; Nakamura, I; Tobe, K; Uno, S | 3 |
| Aubrey-Bassler, K; Chibrikov, E; Curnew, D; Donnan, JR; Gamble, JM; Grandy, CA; Hache, J; Johnston, K; Marra, CA; Nguyen, H; Swab, M | 1 |
| Isaka, H; Kaku, K; Sakatani, T; Toyoshima, J | 3 |
| Tahara, A; Takakura, S; Takasu, T; Yokono, M | 1 |
| Baba, Y; Hashimoto, N; Hattori, A; Horikoshi, T; Ide, K; Ide, S; Ishibashi, R; Ishikawa, K; Ishikawa, T; Kitamoto, T; Kobayashi, A; Kobayashi, K; Koshizaka, M; Maezawa, Y; Nagashima, K; Nakamura, S; Newby, LK; Ogino, J; Ohara, E; Onishi, S; Sakamoto, K; Sato, Y; Shimada, F; Shimofusa, R; Shoji, M; Takahashi, S; Takemoto, M; Tokuyama, H; Uchida, D; Yamaga, M; Yokoh, H; Yokote, K | 2 |
| Kitamura, K; Miyachi, Y; Mori, K; Nakamura, S; Ogawa, Y; Shiba, K; Tsuchiya, K | 1 |
| Hwang, YC; Kim, JH; Lee, BW; Lee, WJ | 1 |
| Ito, K; Kashiwagi, Y; Kimura, H; Nagoshi, T; Oi, Y; Tanaka, TD; Tanaka, Y; Yoshii, A; Yoshimura, M; Yoshino, T | 1 |
| Atsumi, T; Miyoshi, H; Nakamura, A; Takahashi, K; Takase, T; Yamamoto, C; Yamauchi, Y; Yokota, I | 1 |
| Moradi-Marjaneh, R; Paseban, M; Sahebkar, A | 1 |
| Chen, M; Chen, W; Chen, Y; Li, P; Wang, B; Wang, G | 1 |
| Ishihara, H; Kosakai, Y; Sugitani, T; Yamaguchi, S | 1 |
| Chen, X; Ouyang, J; Wang, H; Yang, J; Yao, G | 1 |
| Fujimura-Tanaka, Y; Hamaguchi, Y; Hamanoue, N; Horikawa, T; Inoue, R; Iwaya, C; Kawanami, D; Kawanami, T; Komatsu, S; Motonaga, R; Nomiyama, T; Numata, T; Tanabe, M; Yanase, T | 1 |
| Fukuda, S; Hosokawa, K; Ida, A; Isomoto, H; Iyama, T; Kanda, T; Koda, M; Mae, Y; Matono, T; Sugihara, T; Takata, T; Taniguchi, S; Yamamoto, M | 1 |
| Nakade, J; Nakamura, M; Okajima, M; Taniguchi, T; Toyama, T | 1 |
| Abe, I; Abe, M; Fujii, H; Kobayashi, K; Kudo, T; Minezaki, M; Mukoubara, S; Ochi, K; Ohe, K; Ohishi, H; Ohnishi, Y; Shinagawa, T; Sugimoto, K; Takashi, Y; Yamao, Y | 1 |
| Fukuda, K; Koepsell, H; Masuda, T; Muto, S; Nagata, D; Ohara, K; Vallon, V; Watanabe, M | 1 |
| Ebihara, K; Ishibashi, S; Nagashima, S; Okada, K; Saito, N; Takahashi, M; Wakabayashi, T | 1 |
| Inoue, T; Kusakabe, T; Odori, S; Satoh-Asahara, N; Shimatsu, A; Tanaka, M; Yamakage, H | 1 |
| Amemiya, H; Asakura, T; Iemitsu, K; Ishikawa, M; Ito, S; Kanamori, A; Kaneshiro, M; Kawata, T; Kubota, A; Machimura, H; Matsuba, I; Matsuzawa, Y; Minagawa, F; Minami, N; Miyakawa, M; Mokubo, A; Shinoda, K; Takai, M; Takeda, H; Takihata, M; Takuma, T; Tanaka, K; Tanaka, Y; Terauchi, Y | 1 |
| Dohi, K; Fujimoto, N; Fukuoka, S; Ishiyama, M; Ito, M; Moriwaki, K; Omori, T; Takeuchi, T | 1 |
| Isaka, H; Kaibara, A; Saito, M; Sakatani, T; Toyoshima, J | 1 |
| Ahmed, MA; Chen, H; Liu, D; Song, F; Wu, H | 1 |
| Mori-Anai, K; Nakada, T; Nakamaru, Y; Saito, R; Takahata, T; Tashima, Y | 1 |
| Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Habu, M; Kurozumi, A; Okada, Y; Tanaka, Y | 1 |
| Fujihara, K; Furukawa, K; H Yamada, M; Hatta, M; Ikarashi, T; Iwanaga, M; Katagiri, T; Kitazawa, M; Matsunaga, S; Sone, H; Suzuki, H; Tanaka, S; Yamada, T; Yamamoto, M | 1 |
| Engel, SS; Kadowaki, T; Kaku, K; Kaufman, KD; O'Neill, EA; Okamoto, T; Sato, A; Seino, Y; Shirakawa, M | 2 |
| Bae, J; Cha, BS; Kang, ES; Lee, BW; Lee, JY; Lee, M; Lee, YH; Shin, E | 1 |
| Tahara, A | 2 |
| Inoue, D; Inoue, R; Nangaku, M; Nishi, H | 1 |
| Alkabbani, W; Gamble, JM | 1 |
| Mori, K; Nakamura, S; Ogawa, Y; Okuma, H; Sekine, T; Tsuchiya, K | 1 |
| Fushimi, Y; Kaku, K; Kaneto, H; Katakura, Y; Kimura, T; Kohara, K; Mashiko, A; Mune, T; Nakanishi, S; Obata, A; Sanada, J; Shimoda, M; Tatsumi, F | 1 |
| Aishima, S; Anzai, K; Eguchi, Y; Fujii, H; Hyogo, H; Imajo, K; Isoda, H; Kage, M; Kawaguchi, A; Kawanaka, M; Kessoku, T; Kitajima, Y; Kubotsu, Y; Kurai, O; Nakajima, A; Nakajima, T; Nonaka, M; Oeda, S; Ono, M; Tajiri, R; Takahashi, H; Takamori, A; Tanaka, K; Yoneda, M | 1 |
| Arima, H; Banno, R; Hagiwara, D; Ito, Y; Iwama, S; Kobayashi, T; Mizoguchi, A; Onoue, T; Suga, H; Sugiyama, M; Sun, R; Takagi, H; Taki, K; Tsunekawa, T; Yaginuma, H | 1 |
| Ishihara, H; Kohno, G; Koike, M; Saito, H; Takubo, M; Watanabe, K | 1 |
| Anno, M; Fujioka, Y; Imamura, T; Ito, Y; Izawa, S; Kato, M; Kitao, S; Matsumoto, K; Matsuzawa, K; Nakamura, R; Okura, H; Okura, T; Shoji, K; Taniguchi, SI; Ueta, E; Yamamoto, K | 1 |
| Fujihara, S; Fujita, K; Haba, R; Himoto, T; Iwama, H; Masaki, T; Morishita, A; Nakahara, M; Nishiyama, A; Okano, K; Ono, M; Oura, K; Shi, T; Tadokoro, T; Takuma, K; Tani, J | 1 |
| Akasaka, H; Fujio, Y; Fukuda, M; Iwakura, K; Kamide, K; Nakatani, S; Ogihara, T; Okamura, A; Rakugi, H; Shintani, A; Sugimoto, K; Takiuchi, S; Taniuchi, S; Yamamoto, K | 1 |
| Anzai, K; Takahashi, H | 1 |
| de Knegt, RJ; van Kleef, LA | 1 |
| Higashi, Y; Hirai, H; Hisauchi, I; Inagaki, S; Kamei, N; Kono, T; Kurozumi, A; Maruhashi, T; Node, K; Okada, Y; Oshita, C; Shimabukuro, M; Sonoda, S; Sugimoto, K; Taguchi, I; Takahashi, K; Tanaka, A; Teragawa, H; Torimoto, K | 1 |
21 review(s) available for glucose, (beta-d)-isomer and ipragliflozin
| Article | Year |
|---|---|
Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.
Topics: Animals; Benzhydryl Compounds; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Insulin Resistance; Kidney; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Topics: Animals; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
[Sodium-glucose co-transporter-2 inhibitors: from the bark of apple trees and familial renal glycosuria to the treatment of type 2 diabetes mellitus].
Topics: Adsorption; Animals; Benzhydryl Compounds; Biological Transport, Active; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Drugs, Investigational; Glucose; Glucosides; Glycosides; Glycosuria; Glycosuria, Renal; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Malus; Phlorhizin; Phytotherapy; Plant Bark; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2013 |
Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Topics: Administration, Oral; Benzhydryl Compounds; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucose; Glucosides; Humans; Hypoglycemic Agents; Insulin; Kidney; Molecular Structure; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Clinical pharmacokinetics and pharmacodynamics of the novel SGLT2 inhibitor ipragliflozin.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Drug Interactions; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2015 |
[Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Design; Glucosides; Humans; Insulin-Secreting Cells; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
First case of drug eruption due to ipragliflozin: Case report and review of the literature.
Topics: Aged; Diabetes Mellitus; Drug Eruptions; Glucosides; Humans; Hypoglycemic Agents; Male; Thiophenes | 2017 |
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
Topics: Benzhydryl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Elevated serum magnesium associated with SGLT2 inhibitor use in type 2 diabetes patients: a meta-analysis of randomised controlled trials.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Magnesium; Male; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Kidney Tubules, Proximal; Lipids; Male; Middle Aged; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Time to Target Uric Acid to Retard Chronic Kidney Disease Progression.
Topics: Allopurinol; Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Disease Progression; Enzyme Inhibitors; Febuxostat; Glucosides; Gout Suppressants; Humans; Hyperuricemia; Monosaccharide Transport Proteins; Nitriles; Oxidative Stress; Pyridines; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Uric Acid; Xanthine Oxidase | 2018 |
Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Outcome Assessment, Health Care; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Topics: Acute Kidney Injury; Amputation, Surgical; Benzhydryl Compounds; Canagliflozin; Diabetic Ketoacidosis; Fractures, Bone; Glucosides; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinary Tract Infections | 2019 |
Natural products with SGLT2 inhibitory activity: Possibilities of application for the treatment of diabetes.
Topics: Benzhydryl Compounds; Biological Products; Canagliflozin; Diabetes Mellitus; Glucosides; Humans; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Efficacy and safety of ipragliflozin as add-on to metformin for type 2 diabetes: a meta-analysis of double-blind randomized controlled trials.
Topics: Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Thiophenes | 2019 |
Adverse Drug Events Observed with the Novel Sodium/Glucose Co-Transporter 2 Inhibitor Ipragliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Studies.
Topics: Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucosides; Humans; Pharmaceutical Preparations; Sodium; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Thiophenes | 2020 |
Profile of Ipragliflozin, an Oral SGLT-2 Inhibitor for the Treatment of Type 2 Diabetes: The Evidence to Date.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
41 trial(s) available for glucose, (beta-d)-isomer and ipragliflozin
| Article | Year |
|---|---|
Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fructosamine; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2011 |
Effect of Ipragliflozin (ASP1941), a novel selective sodium-dependent glucose co-transporter 2 inhibitor, on urinary glucose excretion in healthy subjects.
Topics: Adult; Blood Glucose; Blood Pressure Determination; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Glucose; Glucosides; Glycosuria; Heart Rate; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Middle Aged; Placebos; Sex Factors; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Thiophenes; Young Adult | 2011 |
No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Triazoles | 2012 |
Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Europe; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2012 |
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Europe; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Thiophenes; Time Factors; Treatment Outcome; United States | 2013 |
Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Topics: Adult; Aza Compounds; Black or African American; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Electrocardiography; Female; Fluoroquinolones; Glucosides; Healthy Volunteers; Heart Conduction System; Heart Rate; Humans; Male; Middle Aged; Moxifloxacin; Quinolines; Thiophenes; White People; Young Adult | 2013 |
Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study.
Topics: Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Placebos; Thiophenes | 2015 |
Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Area Under Curve; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Thiophenes; Tissue Distribution; Young Adult | 2014 |
A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Renal Insufficiency; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Ipragliflozin as an Initial Therapy in Drug Naïve Subjects with Type 2 Diabetes.
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Prospective Studies; Thiophenes; Uracil | 2016 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Topics: Asian People; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Metformin; Middle Aged; Pioglitazone; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones; Thiophenes; Treatment Outcome | 2016 |
Efficacy, safety, and tolerability of ipragliflozin in Asian patients with type 2 diabetes mellitus and inadequate glycemic control with metformin: Results of a phase 3 randomized, placebo-controlled, double-blind, multicenter trial.
Topics: Asian People; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Male; Metformin; Thiophenes; Treatment Outcome | 2016 |
Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.
Topics: Adiponectin; Aged; Asian People; Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Reproductive Tract Infections; Thiophenes; Treatment Outcome; Urinary Tract Infections | 2016 |
Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.
Topics: Adult; Aged; Biomarkers; Carotid Artery Diseases; Carotid Artery, Common; Carotid Intima-Media Thickness; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome; Young Adult | 2016 |
Preventive effect of ipragliflozin on nocturnal hypoglycemia in patients with type 2 diabetes treated with basal-bolus insulin therapy: An open-label, single-center, parallel, randomized control study.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Middle Aged; Pyrazoles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Effect of 24-week treatment with ipragliflozin on proinsulin/C-peptide ratio in Japanese patients with type 2 diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Middle Aged; Proinsulin; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Efficacy and safety of ipragliflozin and metformin for visceral fat reduction in patients with type 2 diabetes receiving treatment with dipeptidyl peptidase-4 inhibitors in Japan: a study protocol for a prospective, multicentre, blinded-endpoint phase IV
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Metformin; Prospective Studies; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.
Topics: Administration, Oral; Aged; Asian People; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Prospective Studies; Thiophenes; Treatment Outcome; Waist Circumference | 2018 |
Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pioglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome; Young Adult | 2017 |
Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Topics: Activities of Daily Living; Aged; Benzhydryl Compounds; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Glargine; Japan; Male; Membrane Transport Modulators; Middle Aged; Monitoring, Ambulatory; Risk; ROC Curve; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Topics: Adiponectin; Adult; Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes treated with ipragliflozin: a pooled analysis of six randomized, placebo-controlled trials.
Topics: Aged; Blood Glucose; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Japan; Male; Middle Aged; Risk Factors; Thiophenes; Treatment Outcome | 2018 |
Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Metformin; Middle Aged; Republic of Korea; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Young Adult | 2018 |
Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open-label, active-controlled study.
Topics: Adult; Aged; Asian People; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Male; Middle Aged; Sitagliptin Phosphate; Thiophenes | 2018 |
A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Russia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Topics: Adipose Tissue; Adult; Aged; Biomarkers; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Muscle, Skeletal; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 1; Dose-Response Relationship, Drug; Female; Glucosides; Glycosuria; Humans; Japan; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomized controlled
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Metformin; Middle Aged; Prospective Studies; Single-Blind Method; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2019 |
Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
Topics: Adult; Body Weight; Diabetes Mellitus, Type 1; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Male; Middle Aged; Thiophenes | 2019 |
Long-term (52-week) efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open-label extension of a phase III study.
Topics: Aged; Asian People; Diabetes Mellitus, Type 1; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Insulin; Japan; Male; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Trans-Activators; Treatment Outcome | 2020 |
Beneficial Effects of Ipragliflozin on the Renal Function and Serum Uric Acid Levels in Japanese Patients with Type 2 Diabetes: A Randomized, 12-week, Open-label, Active-controlled Trial.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Drug Administration Schedule; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Male; Middle Aged; Renal Insufficiency, Chronic; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Uric Acid; Young Adult | 2020 |
Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME-V study).
Topics: Adult; Aged; Biomarkers; Blood Glucose; Bone and Bones; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Muscles; Prognosis; Prospective Studies; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2021 |
Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Female; Glucose; Glucosides; Humans; Intestinal Absorption; Kidney; Male; Middle Aged; Models, Biological; Postprandial Period; Pyrazoles; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidines; Thiophenes; Young Adult | 2020 |
A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
A randomized, placebo-controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Hypoglycemic Agents; Japan; Metformin; Middle Aged; Sitagliptin Phosphate; Thiophenes; Treatment Outcome | 2021 |
Ipragliflozin Improves the Hepatic Outcomes of Patients With Diabetes with NAFLD.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycemic Control; Humans; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2022 |
The sodium-glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucosides; Humans; Insulin; Insulin Resistance; Japan; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2022 |
Effects of ipragliflozin on left ventricular diastolic function in patients with type 2 diabetes and heart failure with preserved ejection fraction: The EXCEED randomized controlled multicenter study.
Topics: Aged; Diabetes Mellitus, Type 2; Glucosides; Heart Failure; Humans; Natriuretic Peptide, Brain; Stroke Volume; Thiophenes; Ventricular Function, Left | 2022 |
Effect of ipragliflozin on endothelial dysfunction in patients with type 2 diabetes and chronic kidney disease: A randomized clinical trial (PROCEED).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Renal Insufficiency, Chronic | 2023 |
101 other study(ies) available for glucose, (beta-d)-isomer and ipragliflozin
| Article | Year |
|---|---|
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Topics: Animals; Blood Glucose; Carbohydrate Metabolism; CHO Cells; Cricetinae; Cricetulus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Gastrointestinal Tract; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Mice; Mice, Inbred ICR; Phlorhizin; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Topics: Animals; Blood Glucose; CHO Cells; Cricetinae; Diabetes Mellitus, Type 2; Disease Models, Animal; Dose-Response Relationship, Drug; Glucosides; Humans; Hypoglycemic Agents; Inhibitory Concentration 50; Male; Mice; Molecular Structure; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2012 |
Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucose; Glucose Tolerance Test; Glucosides; Hypoglycemic Agents; Insulin; Kidney; Male; Mice; Mice, Inbred ICR; Niacinamide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes | 2012 |
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Female; Glomerular Filtration Rate; Glucose; Glucosides; Glycosuria; Humans; Male; Middle Aged; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Tolerance Test; Glucosides; Glycosuria; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Insulin; Insulin Resistance; Insulin Secretion; Male; Mice; Obesity; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
Sodium glucose transporter 2 inhibition: a new approach to diabetes treatment.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycosides; Humans; Hypoglycemia; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Topics: Female; Glucosides; Humans; Liver; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2013 |
SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Topics: Adiposity; Animals; Anti-Obesity Agents; Biomarkers; Blood Glucose; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Fatty Acids; Glucosides; Glycosuria; Hypoglycemic Agents; Lipid Metabolism; Obesity; Oxidation-Reduction; Rats; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Up-Regulation; Weight Loss | 2014 |
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Topics: Albuminuria; Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fatty Liver; Glomerular Filtration Rate; Glucose Intolerance; Glucosides; Hyperglycemia; Hyperlipidemias; Hypoglycemic Agents; Inflammation; Kidney; Liver; Male; Oxidative Stress; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes | 2014 |
Ipragliflozin: first global approval.
Topics: Animals; Diabetes Mellitus, Type 2; Drug Approval; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemic Agents; Japan; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Mice, Transgenic; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2015 |
Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin.
Topics: Adult; Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucose Tolerance Test; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Insulin-Secreting Cells; Japan; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Increased urine output by ipragliflozin in a non-diabetic patient with a diuretic-resistant heart failure.
Topics: Diabetes Mellitus; Diuresis; Diuretics; Dose-Response Relationship, Drug; Drug Resistance; Female; Glucosides; Heart Failure; Humans; Middle Aged; Stroke Volume; Thiophenes | 2015 |
Glycosuria medicated with ipragliflozin and nifedipine or ipragliflozin and candesartan: a case report.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Calcium Channel Blockers; Drug Therapy, Combination; Glucosides; Glycosuria; Humans; Male; Middle Aged; Nifedipine; Tetrazoles; Thiophenes; Treatment Outcome | 2014 |
Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
Topics: Amino Acids; Animals; Choline Deficiency; Food, Formulated; Glucosides; Hydroxyproline; Hypoglycemic Agents; Inflammation; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rats; Sodium-Glucose Transporter 2 Inhibitors; Thiazolidinediones; Thiophenes; Triglycerides | 2015 |
A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats.
Topics: Animals; Chromatography, Liquid; Drug Stability; Glucosides; Limit of Detection; Linear Models; Male; Rats; Rats, Wistar; Reproducibility of Results; Sodium-Glucose Transporter 2 Inhibitors; Tandem Mass Spectrometry; Thiophenes | 2015 |
Diuretic effects of sodium-glucose cotransporter 2 inhibitor in patients with type 2 diabetes mellitus and heart failure.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diuretics; Female; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice.
Topics: Animals; Biomarkers; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred ICR; Niacinamide; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes; Time Factors | 2016 |
SGLT2 inhibitors provide an effective therapeutic option for diabetes complicated with insulin antibodies.
Topics: Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Insulin Antibodies; Male; Middle Aged; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucosides; Hypoglycemic Agents; Insulin Resistance; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Product Surveillance, Postmarketing; Surveys and Questionnaires; Thiophenes | 2016 |
Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Disease Progression; Glucosides; Hyperglycemia; Hypoglycemic Agents; Male; Rats; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Pep
Topics: Alanine Transaminase; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucagon-Like Peptide 1; Glucosides; Humans; Incretins; Liver Cirrhosis; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Retrospective Studies; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes; Tissue Distribution | 2016 |
Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Topics: Adipose Tissue; Adult; Animals; Body Weight; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Evaluation, Preclinical; Energy Intake; Epididymis; Glucose; Glucosides; Humans; Hyperphagia; Hypoglycemic Agents; Insulin Resistance; Leptin; Lipids; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2016 |
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Topics: Animals; Body Weight; Cell Proliferation; Cells, Cultured; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glucosides; Hepatic Stellate Cells; Hypoglycemic Agents; Insulin Resistance; Liver; Liver Cirrhosis, Experimental; Male; Obesity; Organ Size; Rats, Inbred OLETF; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.
Topics: Adult; Aged; Body Composition; Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Japan; Male; Middle Aged; Obesity; Thiophenes; Young Adult | 2016 |
Renal threshold for glucose reabsorption predicts diabetes improvement by sodium-glucose cotransporter 2 inhibitor therapy.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2016 |
[Efficacy of Ipragliflozin in Patients with Steroid-Induced Hyperglycemia during Cancer Chemotherapy].
Topics: Antiemetics; Blood Glucose; Chemoradiotherapy; Dexamethasone; Esophageal Neoplasms; Glucosides; Humans; Hyperglycemia; Male; Middle Aged; Neoplasm Staging; Thiophenes | 2016 |
Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
Topics: Animals; Body Weight; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Experimental; Diet, Carbohydrate-Restricted; Energy Intake; Fatty Acid Synthases; Forkhead Box Protein O1; Gluconeogenesis; Glucose Tolerance Test; Glucosides; Glycogen; Hyperglycemia; Insulin Resistance; Kidney; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Obesity; RNA, Messenger; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triglycerides; Up-Regulation | 2016 |
Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury.
Topics: Brain Injuries, Traumatic; Diabetes Mellitus; Diabetic Nephropathies; Fludrocortisone; Glucosides; Humans; Hyponatremia; Insulin; Male; Middle Aged; Sodium; Thiophenes | 2016 |
Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Thiophenes; Young Adult | 2016 |
Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.
Topics: Aged; Aged, 80 and over; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Product Surveillance, Postmarketing; Risk Factors; Surveys and Questionnaires; Thiophenes | 2016 |
Predictors of response to ipragliflozin treatment in patients with type 2 diabetes mellitus.
Topics: Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Topics: Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glucosides; Homeostasis; Humans; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Thiophenes | 2016 |
Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor.
Topics: Adipose Tissue; Animals; Body Weight; Glucosides; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2016 |
Amelioration of fatty liver index in patients with type 2 diabetes on ipragliflozin: an association with glucose-lowering effects.
Topics: Adiposity; Adult; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Japan; Lipotropic Agents; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prospective Studies; Severity of Illness Index; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Canagliflozin as an Initial Therapy in Drug-Naïve Subjects with Type 2 Diabetes Mellitus: A Potential Involvement of Atherogenic Lipids in its Glycemic Efficacy.
Topics: Atherosclerosis; Blood Glucose; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Thiophenes; Triglycerides | 2017 |
Sodium-Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case Report.
Topics: Adult; Diabetes Mellitus; Fatty Liver; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Lipodystrophy; Male; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Mechanism of the blood pressure-lowering effect of sodium-glucose cotransporter 2 inhibitors in obese patients with type 2 diabetes.
Topics: Adult; Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Male; Middle Aged; Obesity; Plasma Volume; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Topics: Absorptiometry, Photon; Adipose Tissue; Animals; Body Composition; Diabetes Mellitus, Type 2; Diet, High-Fat; Eating; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2017 |
Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
Topics: Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Ketosis; Obesity; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2017 |
Insulin stimulates uric acid reabsorption via regulating urate transporter 1 and ATP-binding cassette subfamily G member 2.
Topics: Animals; Anion Transport Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; Blood Glucose; Cell Line; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Glucosides; Hypoglycemic Agents; Insulin; Kidney Tubules; Male; Rats, Sprague-Dawley; Renal Elimination; Renal Reabsorption; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Streptozocin; Thiophenes; Time Factors; Uric Acid | 2017 |
Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Humans; Intra-Abdominal Fat; Lipids; Liver; Magnetic Resonance Spectroscopy; Male; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Tomography, X-Ray Computed | 2017 |
The Improvement of the Hepatic Histological Findings in a Patient with Non-alcoholic Steatohepatitis with Type 2 Diabetes after the Administration of the Sodium-glucose Cotransporter 2 Inhibitor Ipragliflozin.
Topics: Aged; Alanine Transaminase; Diabetes Mellitus, Type 2; Female; Ferritins; Glucosides; Humans; Hypoglycemic Agents; Liver Function Tests; Non-alcoholic Fatty Liver Disease; Sodium-Glucose Transporter 2; Thiophenes | 2017 |
Time-dependent effects of ipragliflozin on behaviour and energy homeostasis in normal and type 2 diabetic rats: continuous glucose telemetry analysis.
Topics: Animals; Blood Glucose; Body Temperature; Circadian Rhythm; Diabetes Mellitus, Type 2; Drinking; Eating; Energy Metabolism; Glucosides; Glycosuria; Hypoglycemic Agents; Male; Rats; Rats, Wistar; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2017 |
Switching from low-dose thiazide diuretics to sodium-glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension.
Topics: Aged; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Antidiabetic and antiobesity effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed sugar solution.
Topics: Adipose Tissue; Animal Feed; Animals; Body Weight; Diabetes Mellitus, Type 2; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Obesity; Sodium-Glucose Transporter 2 Inhibitors; Solutions; Sugars; Thiophenes | 2018 |
Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Heart Rate; Humans; Hypoglycemic Agents; Japan; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Product Surveillance, Postmarketing; Registries; Thiophenes; Treatment Outcome; Triglycerides | 2018 |
Ipragliflozin improves mitochondrial abnormalities in renal tubules induced by a high-fat diet.
Topics: Animals; Diet, High-Fat; Energy Intake; Glucosides; Kidney Diseases; Kidney Tubules; Male; Mice; Mice, Inbred C57BL; Mitochondria; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Effects of the SGLT2 inhibitor ipragliflozin on various diabetic symptoms and progression of overt nephropathy in type 2 diabetic mice.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucose; Glucosides; Hypoglycemic Agents; Kidney; Male; Mice, Inbred ICR; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Safety and efficacy of ipragliflozin in elderly versus non-elderly Japanese patients with type 2 diabetes mellitus: a subgroup analysis of the STELLA-LONG TERM study.
Topics: Aged; Asian People; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Japan; Kidney Diseases; Lipoproteins, LDL; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Skin Diseases; Thiophenes; Treatment Outcome | 2018 |
Antidiabetic effects of SGLT2 inhibitor ipragliflozin in type 2 diabetic mice fed diets containing different carbohydrate contents.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Dietary Carbohydrates; Glucosides; Hypoglycemic Agents; Mice; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure: A case report.
Topics: Aged, 80 and over; Body Weight; Glucosides; Heart Failure; Hospitalization; Humans; Male; Myocardial Perfusion Imaging; Sympathetic Nervous System; Thiophenes; Treatment Outcome | 2018 |
Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice.
Topics: Animals; Glucosides; Kidney; Male; Mice; Mice, Inbred BALB C; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glucosides; Hypertension; Kidney; Losartan; Male; Mice, Inbred C57BL; Nephrectomy; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Protective Effect of Ipragliflozin on Pancreatic Islet Cells in Obese Type 2 Diabetic db/db Mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Fatty Acids; Glucosides; Glycated Hemoglobin; Hypoglycemic Agents; Insulin; Islets of Langerhans; Lipid Metabolism; Male; Mice; Mice, Obese; Obesity; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triglycerides | 2018 |
Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
Topics: Animals; Body Composition; Diabetes Mellitus, Type 2; Disease Models, Animal; Diuresis; Drinking; Eating; Epithelial Sodium Channels; Glucosides; Male; Natriuresis; Rats, Sprague-Dawley; Sodium; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Hydrogen Exchanger 3; Thiophenes; Time Factors; Water-Electrolyte Balance | 2018 |
Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors.
Topics: Animals; Glucose; Glucose Transporter Type 2; Glucosides; Humans; Hypoglycemic Agents; Japan; Rats; Skin Diseases; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Subcutaneous Tissue; Thiophenes; Tissue Distribution | 2018 |
Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Eating; Ghrelin; Glucosides; Hypoglycemic Agents; Male; Postprandial Period; Rats; Rats, Wistar; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome | 2018 |
Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
Topics: Animals; Blood Glucose; Caloric Restriction; Citric Acid Cycle; Diabetes Mellitus, Experimental; Glucose; Glucosides; Kidney; Male; Mice; Mice, Obese; Oxidative Stress; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2018 |
Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes | 2019 |
A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Anisoles; Cell Polarity; Ceramides; Diet, High-Fat; Down-Regulation; Glucosides; Interleukin-15; Intracellular Signaling Peptides and Proteins; Ketone Bodies; Lipids; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Phenotype; Phosphoenolpyruvate Carboxykinase (GTP); Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, CCR2; Signal Transduction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sphingomyelins; Thiophenes; Up-Regulation | 2018 |
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results).
Topics: Aged; Alanine Transaminase; Alkaline Phosphatase; Asian People; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats.
Topics: Animals; Autonomic Nervous System; Blood Pressure; Cardiovascular System; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Glucosides; Heart Rate; Rats; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Urinalysis | 2019 |
Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open-label study (SOAR-KOBE Study).
Topics: Appetite; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Eating; Female; Follow-Up Studies; Ghrelin; Glucosides; Glycated Hemoglobin; Glycemic Index; Humans; Leptin; Male; Middle Aged; Prognosis; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Safety and efficacy of tofogliflozin in Japanese patients with type 2 diabetes mellitus in real-world clinical practice: Results of 3-month interim analysis of a long-term post-marketing surveillance study (J-STEP/LT).
Topics: Adolescent; Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Prognosis; Prospective Studies; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Young Adult | 2019 |
Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3-month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabet
Topics: Biomarkers; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Product Surveillance, Postmarketing; Prognosis; Safety; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Weight Loss | 2019 |
Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Topics: Body Weight; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Liver Function Tests; Longitudinal Studies; Male; Middle Aged; Pharmacovigilance; Product Surveillance, Postmarketing; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
In Vitro Pharmacological Profile of Ipragliflozin, a Sodium Glucose Co-transporter 2 Inhibitor.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Glucosides; Humans; Molecular Structure; Phlorhizin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice.
Topics: Adipocytes; Adipogenesis; Adipose Tissue; Adiposity; Animals; Cells, Cultured; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Fibrosis; Glucosides; Inflammation Mediators; Insulin Resistance; Macrophages; Male; Mice, Inbred C57BL; Mice, Knockout, ApoE; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Obesity; Paracrine Communication; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Vascular Remodeling; Vascular System Injuries | 2019 |
A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Topics: Adult; Aged; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glucosides; Glycated Hemoglobin; Glycosuria; Humans; Hypoglycemic Agents; Male; Middle Aged; Prospective Studies; Republic of Korea; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Young Adult | 2019 |
Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Topics: Animals; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diet, High-Fat; Disease Models, Animal; Glucose Transporter Type 4; Glucosides; Insulin Resistance; Isolated Heart Preparation; Male; Mice, Inbred C57BL; Myocardial Reperfusion Injury; Myocytes, Cardiac; Obesity; Phlorhizin; Signal Transduction; Sodium-Glucose Transporter 1; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Factors with remission of fatty liver in patients with type 2 diabetes treated with ipragliflozin.
Topics: Aged; Body Mass Index; Diabetes Mellitus, Type 2; Fatty Liver; Female; gamma-Glutamyltransferase; Glucosides; Humans; Male; Middle Aged; Remission Induction; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Triglycerides; Waist Circumference | 2019 |
Open-Label Study to Assess the Efficacy of Ipragliflozin for Reducing Insulin Dose in Patients with Type 2 Diabetes Mellitus Receiving Insulin Therapy.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Thiophenes | 2019 |
Ipragliflozin as an add-on therapy in type 2 diabetes mellitus patients: An evidence-based pharmacoeconomics evaluation.
Topics: Diabetes Mellitus, Type 2; Drug Therapy, Combination; Economics, Pharmaceutical; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Acute and Direct Effects of Sodium-Glucose Cotransporter 2 Inhibition on Glomerular Filtration Rate in Spontaneously Diabetic Torii Fatty Rats.
Topics: Animals; Blood Glucose; Blood Pressure; Chlorides; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glomerular Filtration Rate; Glucosides; Heart Rate; Male; Rats, Sprague-Dawley; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Gene Knockdown Techniques; Glucosides; Humans; MCF-7 Cells; Membrane Potential, Mitochondrial; Patch-Clamp Techniques; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Progression; Drug Therapy, Combination; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Pioglitazone; Rodentia; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules.
Topics: Animals; Apoptosis; Disease Models, Animal; Down-Regulation; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Glucosides; Heat-Shock Proteins; Male; Mice; Non-alcoholic Fatty Liver Disease; Renal Insufficiency, Chronic; Thiophenes; Transcription Factor CHOP; Triglycerides | 2019 |
Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report.
Topics: Adult; Drug Overdose; Female; Glucosides; Humans; Hypotension; Kidney; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Topics: Aged; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2019 |
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume.
Topics: Animals; Body Fluid Compartments; Body Fluids; Diuresis; Diuretics, Osmotic; Glucosides; Osmosis; Rats; Renal Reabsorption; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Vasopressins; Water | 2020 |
Long-term efficacy of the sodium-glucose cotransporter 2 inhibitor, ipragliflozin, in a case of type A insulin resistance syndrome.
Topics: Adult; Biomarkers; Blood Glucose; Diabetes Mellitus; Female; Glucosides; Glycated Hemoglobin; Humans; Insulin Resistance; Prognosis; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study.
Topics: Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucosides; Glycated Hemoglobin; Humans; Male; Middle Aged; Prognosis; Prospective Studies; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2020 |
Mechanisms and prediction of short-term natriuretic effect of sodium-glucose cotransporter 2 inhibitor in heart failure patients coexisting type 2 diabetes mellitus.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Hospitalization; Humans; Male; Middle Aged; Natriuresis; Natriuretic Agents; Prospective Studies; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2020 |
Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Japan; Product Surveillance, Postmarketing; Thiophenes | 2021 |
Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Topics: Adult; Ambulatory Care; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Female; Glucosides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Monitoring, Ambulatory; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
[Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Topics: Adult; Benzhydryl Compounds; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Female; Glucosides; Glycemic Control; Humans; Hyperglycemia; Male; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Time Factors; Treatment Outcome | 2020 |
Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Energy Metabolism; Glucosides; Male; Mice; Sirtuin 1; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Effects of SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone on fluid retention in type 2 diabetic mice with NASH.
Topics: Animals; Aquaporin 2; Body Fluids; Diabetes Mellitus, Type 2; Diuresis; Drinking; Glucosides; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Organ Size; Osmolar Concentration; Pioglitazone; Sodium; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM).
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Blood Glucose; Diabetes Mellitus, Type 2; Female; gamma-Glutamyltransferase; Glucosides; Glycated Hemoglobin; Humans; Japan; Liver; Liver Function Tests; Male; Middle Aged; Product Surveillance, Postmarketing; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Regional Distribution of Cardiologists and Prescription Patterns of Sodium-Glucose Transporter-2 Inhibitors in Japan.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Canagliflozin; Cardiologists; Cardiovascular System; Data Analysis; Diabetes Mellitus, Type 2; Female; Glucosides; Humans; Japan; Kidney; Male; Prescriptions; Regression Analysis; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Thiophenes | 2021 |
Ipragliflozin Ameliorates Diabetic Nephropathy Associated with Perirenal Adipose Expansion in Mice.
Topics: Adipose Tissue; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Glucosides; Kidney Glomerulus; Male; Mice; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Efficacy and safety of adding ipragliflozin to insulin in Japanese patients with type 1 diabetes mellitus: a retrospective study.
Topics: Adult; Blood Glucose; Diabetes Mellitus, Type 1; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Japan; Middle Aged; Retrospective Studies; Thiophenes; Treatment Outcome | 2021 |
SGLT2 inhibitor ipragliflozin exerts antihyperglycemic effects via the blood glucose-dependent increase in urinary glucose excretion in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose Tolerance Test; Glucosides; Humans; Male; Mice; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Peripheral combination treatment of leptin and an SGLT2 inhibitor improved glucose metabolism in insulin-dependent diabetes mellitus mice.
Topics: Administration, Oral; Animals; Diabetes Mellitus, Type 1; Disease Models, Animal; Drug Therapy, Combination; Glucose; Glucosides; Infusions, Intravenous; Leptin; Male; Mice, Inbred C57BL; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Effects of GLP-1RA and SGLT2i, Alone or in Combination, on Mouse Models of Type 2 Diabetes Representing Different Disease Stages.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Drug Therapy, Combination; Glucagon-Like Peptide-1 Receptor; Glucosides; Hypoglycemic Agents; Insulin-Secreting Cells; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Obese; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2021 |
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Glucose; Diabetes Mellitus, Experimental; Disease Models, Animal; Fasting; Gene Expression Profiling; Gene Expression Regulation; Glucosides; Hepatocytes; Hypoglycemic Agents; Interleukin-1beta; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; MicroRNAs; Non-alcoholic Fatty Liver Disease; Signal Transduction; Streptozocin; Superoxide Dismutase; Thiophenes; Tumor Necrosis Factor-alpha | 2022 |
Reply to the Letter to the editor "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
Topics: Diabetes Mellitus; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Thiophenes | 2022 |
Reply to: "Ipragliflozin improves the hepatic outcomes of patients with diabetes with NAFLD".
Topics: Diabetes Mellitus; Glucosides; Humans; Non-alcoholic Fatty Liver Disease; Thiophenes | 2022 |